Economy

Traders Buy Shares of Regeneron Pharmaceuticals, Inc. (REGN) on Weakness

The institutional investor held 1.59M shares of the health care company at the end of 2017Q2, valued at $779.11M, up from 1.48M at the end of the previous reported quarter. The stock increased 1.57% or $6.79 during the last trading session, reaching $438.17. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping the consensus estimate of $2.67 by $1.50. It is down 25.56% since September 20, 2016 and is uptrending. It has outperformed by 12.17% the S&P500. The firm's revenue for the quarter was up 21.2% on a year-over-year basis. The stock was sold at an average price of $470.00, for a total transaction of $613,350.00. The company was maintained on Wednesday, August 5 by RBC Capital Markets. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.3074804445183 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. About 3.77M shares traded.

Norinchukin Bank The raised its stake in shares of Regeneron Pharmaceuticals, Inc. It has outperformed by 0.70% the S&P500.

Since March 29, 2017, it had 1 insider purchase, and 8 selling transactions for $42.35 million activity. 1,000 shares valued at $482,550 were sold by GOLDSTEIN JOSEPH L on Friday, June 9. Polen Capital Management Llc who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $46.57 billion market cap company. On Thursday, May 25 the insider VAGELOS P ROY sold $4.26M. TH Capital maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Monday, August 10 with "Neutral" rating. Andra Ap reported 0.01% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). (REGN) Might Be a Diamond in the Rough" published on August 22, 2017 as well as Seekingalpha.com's news article titled: "Regeneron - Diversification Efforts Could Soon Yield Results" with publication date: "September 18, 2017. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.89 earnings per share for the current fiscal year. (NYSE:GIS), 1 have Buy rating, 5 Sell and 11 Hold. Therefore 46% are positive. Zacks Investment Research raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating and set a $540.00 target price for the company in a research note on Wednesday, August 9th. As per Wednesday, January 20, the company rating was initiated by Credit Suisse. The rating was upgraded by BTIG Research to "Buy" on Friday, December 16. The firm has "Hold" rating by Deutsche Bank given on Wednesday, February 15. (NYSE:GIS) on Tuesday, July 21 to "Outperform" rating. The stock has "Hold" rating by BMO Capital Markets on Monday, September 11. As per Monday, June 12, the company rating was maintained by Leerink Swann.

North Point Portfolio Managers Corp increased Regeneron Pharmaceuticals (REGN) stake by 2.59% reported in 2017Q2 SEC filing. During the same quarter in the prior year, the business earned $2.82 earnings per share. REGN's profit will be $406.10 million for 28.79 P/E if the $3.79 EPS becomes a reality. State Street Corp increased its holdings in shares of Regeneron Pharmaceuticals by 4.3% in the 1st quarter.

Investors sentiment increased to 1.4 in Q4 2016. Its up 0.29, from 0.96 in 2016Q3.

Several equities analysts have commented on REGN shares. Brown Advisory stated it has 2,640 shares or 0% of all its holdings. Bradley Foster And Sargent Ct owns 61,969 shares. BlackRock Inc. grew its holdings in Regeneron Pharmaceuticals by 0.7% in the second quarter. Oppenheimer has an ownership of 7,007 stocks of the biopharmaceutical firms shares valued $3,441,000 following purchasing an extra 1,199 shares through out the previous quarter, Dupont Capital Management bought a new stake in stocks of Regeneron Pharmaceuticals through out the 2nd valued at roughly $220,000. Aperio Grp Inc Ltd Limited Liability Company reported 27,064 shares stake. Commerzbank Aktiengesellschaft Fi has 24,429 shares for 0.13% of their portfolio. Granite Prtn holds 0.12% or 104,458 shares. Overbrook Management Corp invested 0.13% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Dimensional Fund Limited Partnership owns 155,255 shares for 0.03% of their portfolio. The stock declined 0.75% or $0.39 reaching $51.78 on the news. 70,944 are owned by Van Eck Associate. BlackRock Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 3,331.5% during the first quarter. Moreover, Old Mutual Customised Solutions (Proprietary) has 0.06% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Sg Americas Securities Ltd has invested 0.07% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Investors sentiment increased to 1.38 in 2017 Q2. Its up 0.08, from 0.73 in 2016Q3. Shares for $1.35 million were sold by STAHL NEIL. Appleton Prtnrs Inc Ma reported 1.28% stake. Cibc Corp has 5,207 shares for 0.02% of their portfolio. Nippon Life Insur accumulated 0.03% or 4,011 shares. Cypress Funds Llc acquired 50,000 shares as Hrg Group Inc (HRG)'s stock declined 0.45%. Citadel Advsr Lc has invested 0.07% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). 1,100 are owned by Walleye Trading Ltd Liability Corporation. Moreover, Aull And Monroe Investment Mngmt has 0.25% invested in General Mills, Inc. World Asset Mgmt accumulated 7,345 shares. Bbva Compass Bank holds 0.06% or 15,393 shares in its portfolio.



Like this

loading...
loading...

Latest


22 September 2017
Et si Christopher Froome visait le triplé — Tour d'Italie
Mercredi 20 septembre, il s'élancera avec le dossard de favori du contre-la-montre du championnat du monde de Bergen, en Norvège. C'est ce qu'on appelle se faire voler la vedette.

22 September 2017
US flies advanced warplanes amid tensions with N. Korea
USA nuclear weapons were withdrawn from the Korean peninsula in the early 1990s at the close of the Cold War. President Trump has repeatedly refused to rule out a military strike on North Korea's nuclear facilities.

22 September 2017
Parsons Green Bombing: Police Granted More Time To Question Two Main Suspects
A suicide bomber attacked a concert venue in Manchester in May, killing more than 20 people including children and mothers. Patrols by armed police were increased across the country following the Parsons Green tube attack on Friday.

22 September 2017
Williams Companies, Inc. (The) (WMB) Earning Somewhat Favorable Media Coverage, Report Shows
Capital International Inc decreased Monsanto Co (NYSE:MON) stake by 15,750 shares to 39,800 valued at $4.71M in 2017Q2. Ross Stores, Inc. (ROST) formed double bottom with $58.48 target or 4.00% below today's $60.92 share price.

22 September 2017
Salalima quits as DICT head
In a press conference during his fifth visit to Marawi City on Thursday, the President also confirmed Salalima's resignation. Another Cabinet secretary, former Interior secretary Ismael Sueno, was sacked by Duterte amid allegations of corruption.

22 September 2017
Which Brand Will She Appear on?
Word is that WWE officials already have a storyline for Paige's return and that it will be for the SmackDown brand. WWE star Paige teased on Instagram Tuesday that she is returning to the company following an extended hiatus.

22 September 2017
NV5 Holdings Inc (NASDAQ:NVEE) Shifting Institutional Investors Sentiment
The 14-day RSI is now sitting at 76.66, the 7-day is at 82.58, and the 3-day is spotted at 85.90 for NV5 Global Inc (NVEE). ValuEngine raised NV5 Global from a "hold" rating to a "buy" rating in a research note on Friday, September 15th.

22 September 2017
UBS Asset Management Americas Inc. Boosts Stake in EOG Resources, Inc. (EOG)
Tetrem Capital Management Ltd. owned approximately 0.13% of EOG Resources worth $66,005,000 at the end of the most recent quarter. The energy exploration company reported $0.08 EPS for the quarter, missing the Zacks' consensus estimate of $0.10 by ($0.02).

22 September 2017
Closing Bell: Stocks Higher Despite President Trump's North Korea Aggression
Advancing issues outnumbered declining ones on the NYSE by a 1.26-to-1 ratio; on Nasdaq, a 1.30-to-1 ratio favored advancers. Roughly 6.7 billion shares changed hands on USA exchanges compared with the 6 billion average for the last 20 sessions.

22 September 2017
Price Target Analysis of GoPro, Inc. (GPRO)
Citigroup Inc. restated a neutral rating and set a $10.50 price objective on shares of GoPro in a report on Friday, September 8th. The business had revenue of $296.52 million during the quarter, compared to analysts' expectations of $268.94 million.